Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPACT Extension Study: Survival Data Collection in CA046 Subjects
2013-003866-15Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by Celgene Corporation. Primary endpoint: Overall survival / vital status. Started Dec 2013; status: completed.
02
Drugs
paclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2013-003866-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003866-15.